To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
TOLREMO therapeutics AGPreventing resistance to cancer therapy
TOLREMO therapeutics AG has created ground-breaking scientific knowledge that allows it to pursue its passion to discover and develop novel targeted therapeutics that will meaningfully extend the lives of patients suffering from cancer. TOLREMO is a privately held research-stage biotechnology company. TOLREMO was founded in March 2017 as an ETH Spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin, and Emmanuel Savioz (MBA).
The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug resistance therapies.
TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.
By combining its resistance-breaking add-on therapies with existing cancer drugs, TOLREMO aims to meaningfully extend the lives of patients suffering from different types cancer.
USING SCIENCE TO ELIMINATE THE SEED OF DRUG RESISTANCE
Understanding the molecular mechanisms that initiate drug resistance is paramount to increasing the long-term effectiveness of cancer treatments. Clinical drug response is influenced by spatial heterogeneity, genetic makeup and transcriptional cell states which evolve over time and across the cell population of a tumor. Considering temporal aspects and stochastic cell states during drug resistance development is key to long-lasting therapies. TOLREMO has built a unique drug resistance platform that combines real-world medicine-guided, cutting-edge science with proprietary drug screening modalities and a preclinical validation pipeline. TOLREMO’s drug resistance platform is integrated in a network of academic and clinical partners that further fuel the company’s drug discovery and development engine.
RESISTANCE-BREAKING ADD-ON THERAPIES FOR DURABLE THERAPEUTIC OUTCOMES
TOLREMO leverages its unique drug resistance platform to achieve durable therapeutic responses to a multitude of cancer drugs by co-targeting key drug resistance mechanisms. In two parallel R&D programs the company develops resistance-breaking add-on therapies that extend the clinical benefit of existing cancer drugs. TOLREMO plans to use its molecules alongside diagnostic solutions to ensure that the right patient is treated with the right drug at the right time.
- Cancer drugs